Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Completed · Phase 2 · Has a placebo group

Conditions studied: Migraine, Acute Treatment of Migraine

In brief

The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain") at 2 hours post dose using a four point numeric rating scale (no pain, mild pain, moderate pain, severe pain) while identifying an optimal dose to support the Phase 3 clinical trials.

Key facts

Study ID
NCT01430442
Run by
Pfizer
People needed
1026
Starts
2011-10-01
Expected to finish
2012-05-01
Last updated by the study team
2023-02-28

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.